ClinicalTrials.gg
RecruitingNCT06342895IONICUpdated Aug 12, 2024

Interpretation and Optimization of Nutrition in the Intensive Care Units

An interventional study of Nutritional support prescription and delivery monitoring feedback and Usual care in Nutritional Support, sponsored by Dim3. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-12.

Sponsored by Dim3 · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Despite recommendations, inadequate nutritional intake in intensive care unit (ICU) patients remains frequent and can lead to complications such as infections, increased length of stay, prolonged weaning from ventilation, increased long-term mortality, and decreased quality of life after intensive care. Studies have shown that patients only receive up to 50-60% of prescribed calories and proteins due to many factors leading to nutritional support interruptions such as ICU procedures, physical therapy, transport for imaging or invasive procedures outside the ICU, and nutrition intolerance.

Furthermore, this discrepancy between prescribed and delivered nutrition may go largely unnoticed, due to issues concerning inadequate manual or automated monitoring of delivered nutrition. A joint "Call to Action" by ASPEN, the Academy of Nutrition and Dietetics, and the American Society of Health-System Pharmacists stated that parenteral nutrition errors and their contributing factors could be prevented by improving the functionality of in-house Clinical Decision Support Systems and the interfaces between electronic health records (EHRs), automated preparation devices and pharmacy systems.

Nutrow® is a software package designed to support nutritional management based on the calculation of recommended calorie and protein requirements, real-time calculation and monitoring of calorie and protein prescriptions, real-time calculation and monitoring of calories and protein truly delivered to patients, and information feedback to prescribers. Feedim® is a Medical Device Data System (MDDS), designed by Dim3, which transmits information from enteral feeding pumps to third-party software, such as Nutrow®.

The aim of the study is to assess whether the joint use of Nutrow-Feedim improves the achievement of nutritional objectives in ICU patients prior to oral intake by reducing the discrepancy between prescribed and delivered calories and protein.

02

Conditions studied

  • Nutritional Support

Keywords

  • Intensive Care Unit
  • Protein Calorie Malnutrition
  • Refeeding syndrome
  • Clinical Decision Support Systems
03

In context

Protein-Energy Malnutrition

40 studies on the registry are indexed under Protein-Energy Malnutrition; 7 are open to participants now.

This study's planned enrollment of 144 is above the median of 92 across 30 interventional studies indexed under Protein-Energy Malnutrition.

Browse Protein-Energy Malnutrition studies →

Lead sponsor

This is the only study on the registry with Dim3 as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 and over.
  • French Social Security system registration.
  • First stay in ICU
  • Admitted to the Lille University Hospital Surgical ICU for at least 3 days.
  • Active enteral and/or parenteral nutritional support prescription
  • Patient and/or next-of-kin informed about the study and having consented to participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Age under 18
  • Burn patient
  • Admitted to the ICU with a prior active enteral/parenteral nutritional support before day 3, except trophic nutrition
  • Dying patient, not-to-be-resuscitated order, or other treatment limitation decision at ICU admission
  • Adult under guardianship
  • Department of corrections inmate
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Interventional

    Device: Nutritional support prescription and delivery monitoring feedback

  • Other
    control

    Device: Usual care

Interventions

  • DeviceNutritional support prescription and delivery monitoring feedback

    Real-time availability in an integrated computer interface (Nutrow) of all clinical and biological information related to nutritional support including recommended, prescribed, and delivered calories and proteins and enteral feed delivery transmitted by the Feedim medical device

  • DeviceUsual care

    Usual use of standard clinical and biological information related to nutritional support as available through the ICU electronic health record (i.e. without any calculated information on recommended, prescribed, or received calories and protein, only information on prescribed products and volumes as collected by and presented in the ICU EHR) In this arm, participants, investigators, and healthcare professionals will be blinded to real-time enteral feed volumes that will be collected by the Feedim medical device and transmitted to the electronic study case report form.

06

What researchers measure

Primary outcomes

  1. Mean total daily calories delivered/prescribed ratio (percent)

    Total (enteral+parenteral) prescribed and delivered calories are measured daily (kcal/day). The ratio of mean total daily delivered calories over the study period divided by the mean total daily prescribed calories over the study period will be calculated and expressed as a %

    Time frame: From ICU Day 3 to Day 28 or until any of the following if before day 28: Return to oral intake Discharge from the ICU Death

Secondary outcomes

  1. Mean total daily protein delivered/prescribed ratio (%)

    Total (enteral+parenteral) prescribed and delivered protein are measured daily (g/day). The ratio of total mean daily delivered protein over the study period divided by the mean total daily prescribed protein over the study period will be calculated and expressed as a %

    Time frame: From ICU Day 3 to Day 28 or until any of the following if before day 28: Return to oral intake Discharge from the ICU Death

  2. Mean total daily calories delivered/recommended ratio (percent)

    Total (enteral+parenteral) prescribed and delivered calories are measured daily (kcal/day). The ratio of mean total daily delivered calories over the study period divided by the mean total daily recommended calories (according to guidelines) over the study period will be calculated and expressed as a %

    Time frame: From ICU Day 3 to Day 28 or until any of the following if before day 28: Return to oral intake Discharge from the ICU Death

  3. Mean total daily protein delivered/recommended ratio (percent)

    Total (enteral+parenteral) prescribed and delivered protein are measured daily (g/day). The ratio of mean total daily delivered protein over the study period divided by the mean total daily recommended protein (according to guidelines) over the study period will be calculated and expressed as a %

    Time frame: From ICU Day 3 to Day 28 or until any of the following if before day 28: Return to oral intake Discharge from the ICU Death

  4. Nutritional support duration (days)

    Days on nutritional support (either parenteral and/or enteral) over the study period

    Time frame: From ICU Day 3 to Day 28 or until any of the following if before day 28: Return to oral intake Discharge from the ICU Death

  5. Time to initiation of nutritional support (days)

    Days elapsed from ICU admission (Day 1) to first administration of any nutritional support (either parenteral and/or enteral) over the study period

    Time frame: From ICU Day 3 to Day 28 or until any of the following if before day 28: Return to oral intake Discharge from the ICU Death

  6. Weight (Kg)

    Daily body weight (Kg) as weighed using weighing scale integrated in the ICU-bed

    Time frame: From ICU Day 3 to Day 28 or until any of the following if before day 28: Return to oral intake Discharge from the ICU Death

  7. Day 28 mortality rate

    Patient death during the timeframe

    Time frame: From ICU admission (Day1) to Day 28

  8. ICU length-of-stay (days)

    Days patient present in the ICU

    Time frame: From ICU admission (Day1) to ICU discharge, data censored at Day 28 max

  9. Days on ventilator (days)

    Days patient on ventilator

    Time frame: From ICU admission (Day1) to ICU discharge, data censored at Day 28 max

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2025, 12 months after the start.

Of 16 interventional studies with no phase under Protein-Energy Malnutrition, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 41. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 2, 2024
StartActual
Apr 10, 2024
Primary completionEst.
Apr 2025
CompletionEst.
Sep 2025
Last update
Aug 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06342895
Lead sponsor
Dim3
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Apr 10, 2024
Primary completion
Apr 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Aug 12, 2024

Study contacts

Eric KIPNIS, MD,PhD
Contact
eric.kipnis@chu-lille.fr
+33 (0)3 20 44 59 62
Eric KIPNIS, MD,PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion